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Background: An increased and prolonged duration of pain relief after morphine administra-
tion has been found in elderly patients. Whether this is due to alterations in pharmacokinetics, 
receptor binding proﬁ  le or other factors remains unsolved. The aims were to elucidate the 
pharmacokinetics after intravenous administration of morphine and oxycodone in elderly 
patients older than 70 years.
Methods: A randomized non-blinded study with 16 patients aged older than 70 years scheduled 
for elective hip replacement receiving morphine or oxycodone 0.05 mg/kg as an IV infusion 
over 15 minutes.
Results: A 2-compartment pharmacokinetic model best described the disposition of morphine 
and oxycodone. The estimated elimination half-lives for morphine and oxycodone were (mean 
± SD) 2.7 ± 3.6 (range 0.8–11.6) and 3.1 ± 1.3 (range 1.1–4.8) hr, respectively. Volume of 
distribution at steady state was estimated to be 243 ± 256 and 277 ± 187 L, and clearance to be 
1748 ± 623 and 1206 ± 546 ml/min for morphine and oxycodone, respectively.
Conclusion: The increased and prolonged duration of pain relief after morphine administra-
tion seen in some elderly patients cannot, based on these ﬁ  ndings, be ascribed to changes in 
the pharmacokinetic parameters between elderly and younger patients. Similar for oxycodone, 
no changes in the pharmacokinetic could be found when comparing the parameters found in 
elderly patients with those from younger healthy volunteers. A great variability within the 
individual pharmacokinetic parameters was seen for both drugs. Therefore, we recommend 
that treatment with morphine and oxycodone in elderly patients is initiated very conservatively 
and is titrated slowly to effect.
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Introduction
In developed countries the percentage of the population over 80 years will more than 
triple by 2050. Older people have the highest rates of surgical procedures (Gibson and 
Weiner 2005). Standard postoperative pain treatment is often intravenous administra-
tion of morphine during the ﬁ  rst 24 hours after operation followed by oral sustained 
release morphine. An increased and prolonged duration of pain relief after morphine 
administration has been found in the elderly patients (Bellville et al 1971; Kaiko 1980). 
However, whether this is due to alterations in pharmacokinetics, in receptor binding 
proﬁ  les or to other factors still remains unsolved.
Oxycodone is another opioid, which is widely used in postoperative settings. Its 
main beneﬁ  t over morphine is the lack of active metabolites contributing to the anal-
gesic effect. Morphine and oxycodone are believed to act on different classes of opioid 
receptors and with different afﬁ  nities and different kinetics. The pharmacokinetic of 
morphine in elderly people (age over 60 years) have been investigated in a few studies 
(Berkowitz et al 1975; Stanski et al 1978; Owen et al 1983; Baillie et al 1989; Sear Therapeutics and Clinical Risk Management 2007:3(5) 962
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et al 1989), whereas no studies on the pharmacokinetics of oxy-
codone has so far been conducted in this patient population.
The aims of this study were to elucidate the pharma-
cokinetics after intravenous administration of morphine 
and oxycodone in elderly patients older than 70 years and 
compare this to the literature data on pharmacokinetics of 
morphine and oxycodone of younger people.
Materials and methods
Study design, subjects and blood sampling
The study was conducted as a randomized non-blinded study. 
The Regional Committee on Biomedical Research Ethics 
for Copenhagen County and the Danish Medicines Agency 
approved the study protocol, the informed consent form and 
the subsequent amendments for the study. Verbal and written 
information concerning the study was given to the patients 
and written informed consent was obtained according to the 
ethical principles stated in the Declaration of Helsinki II. 
Study subjects were 16 patients older than 70 years scheduled 
for elective hip replacement. Exclusion criteria included 
mental illness assessed subjectively by a physician, dialysis, 
deviant liver and/or kidney function assessed by deviant 
laboratory values, regular treatment with opioids for pain 
due to osteoarthritis, treatment with morphine, oxycodone or 
codeine from three days prior to the study day, treatment with 
MAO-inhibitors or ﬂ  uoxetine (SSRI-inhibitor) from 2 weeks 
before the study day. Known hypersensitivity to morphine 
or oxycodone was also an exclusion criterion.
The study subjects were asked to be fasting from mid-
night prior to the study day, which was the day before the 
surgery. In the morning, the study subjects received either 
morphine or oxycodone 0.05 mg/kg as an IV infusion over 
15 minutes. The drugs, morphine hydrochloride 10 mg/ml 
(SAD, County Medical Regulatory Ofﬁ  ce I/S, Denmark) and 
oxycodone hydrochloride 10 mg/ml (Oxynorm®, norpharma 
a/s, Denmark) in ampoules of 1 ml were supplied by the hos-
pital pharmacy at Herlev University Hospital. A peripheral 
vein contra lateral to the vein used for drug administration 
was used for blood sampling. Blood samples were collected 
before infusion, at 5, 10, and 15 minutes after the beginning 
of the infusion, and at 5, 10, 15, 30, 60, 90 minutes and 2, 
4, 6, 8, 11, and 24 hours after the end of the infusion period. 
The last blood sample was sampled as close as possible to 
the scheduled time, but before the patient went into surgery. 
The actual sampling times were noted in the individual case 
report form and subsequently used in the pharmacokinetic 
analysis. Blood samples were drawn into dry glass tubes, 
which were placed on ice until centrifugation at 3000 rpm 
for 10 minutes. Serum was separated into tubes, which were 
stored below –20 °C until analysis.
Routine vital signs including blood pressure, pulse rate, 
respiratory rate, and oxygen saturation were obtained at the 
same times as the blood samples were taken until 30 min after 
drug administration. These parameters were also recorded 
in the individual case report form. The study subjects were 
allowed breakfast 60 min after infusion.
LC-MS analyses
Serum samples obtained after morphine administration were 
analyzed for morphine and the metabolites morphine-3-
glucuroninde (M3G) and morphine-6-glucuronide (M6G). 
Serum samples obtained after oxycodone administration were 
analyzed for oxycodone and the metabolites oxymorphone 
and noroxycodone.
Quantiﬁ  cation was done by high-performance liquid chro-
matography (HPLC) using mass spectrometry as the detection 
principle. The LC-MS system used consisted of a Hewlett 
Packard 1100 series chromatograph (Palo Alto, California, 
USA) equipped with a Quatpump, a degasser, column oven 
(colcomp), an autosampler (ALS), a DAD UV detector oper-
ated at 280 nm (bandwidth 16) and a MSD detector. Data 
were collected using the HP ChemStation software, version 
6.03 (Palo Alto, California, USA). The analytical column was 
a reversed phase Synergi 4 µ Polar RP 80A (Phenomenex, 
Torrance, CA, USA) column (4.6 mm I.D. × 150 mm, 4 µm 
particles). A linear gradient system was applied. Eluent A 
consisted of 1% formic acid in MeCN:water (3:97 v/v), eluent 
B of 1% formic acid in MeCN:water (27:73 v/v) and eluent 
C of 1% formic acid in MeCN:water (80:20, v/v). The linear 
gradient was applied from 100% A to 100% B over 4 min. 
One hundred percent B was maintained for 3 min and then 
to 100% C over 1 min and maintained at 100% C for 3 min. 
Finally the gradient returned to 100% A in 1 min. The ﬂ  ow-
rate was 0.5 mL/min. and the total run time was 20 min.
The MSD detector was equipped with an electrospray 
interface and used in positive mode for SIM detection of the 
masses: 286.1 (morphine, and the internal standard hydromor-
phone, which are well separated in the HPLC system), 462.2 
(M-6-G and M-3-G which are well separated in the HPLC 
system), 316.1 (oxycodon), and 302.1 (oxymorphone and 
noroxycodone being well separated in the HPLC system).
The fragmentor voltage was set to 100 V for all masses 
except for mass 462.2 where it was set at 120 V. The voltage 
over the capillary was kept at 3000 V. The temperature of the 
nitrogen drying gas was set to 350 °C with a ﬂ  ow-rate of 13 
L/min. The nebulizer gas pressure was 30 psig.Therapeutics and Clinical Risk Management 2007:3(5) 963
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After addition of the internal standard, hydromorphone, 
serum samples and calibration standards in serum were 
subject to solid phase extraction using 1.0 ml of serum on 
Oasis HLB SPE cartridges (30 mg). The ﬁ  nal eluent was 
evaporated to dryness under nitrogen at ambient temperature 
and the residue was dissolved in 500 µL of eluent A. 25 µL 
was injected onto the HPLC column.
Limit of quantiﬁ  cation (LOQ) for morphine and M3G/
M6G was 3.5 nmol/L and 5.0 nmol/L, respectively. Linearity 
of the calibration curve was proven from 3.5 to 10.000 nmol/L. 
This was used for the detection of M3G. Narrow ranges were 
used for the detection of morphine and M6G, 3.5 to 50 nmol/L 
and 5.0 to 1000 nmol/L, respectively. The LOQ for oxycodone 
was 3.5 nmol/L. The CV of the method determined at three 
concentration levels were in all cases below 15% for the inter-
day variation. Intra-day variations were a little less than the 
inter-day CV but at the same order of magnitude.
Data analysis
Pharmacokinetic analysis
Individual serum concentrations for morphine and oxycodone 
were analyzed using WinNonLin, Version 3.3 (Pharsight 
Corporation, Mountain View, CA, USA). The data was ﬁ  tted 
to 1-, 2- and 3-compartment pharmacokinetic models. Selec-
tion criteria for the ﬁ  nal model was a low Akaike Criteria 
(AIC), a statistical signiﬁ  cant (p < 0.05) improvement of the 
ﬁ  t as determined by the F-test based upon the residual sum 
of squares, and an even distribution of residuals.
The following pharmacokinetic parameter estimates 
were determined using compartmental analysis: systemic 
clearance (CL), volume of distribution at steady state (Vss), 
central compartment volume (V2), peripheral compartment 
volume (V1), and elimination half-life (t½). Area under the 
serum concentration-time curve (AUC) was calculated by 
using the software GraphPad Prism version 4.00 for Windows 
(GraphPad Software, San Diego, California, USA). Intercom-
partmental rate constants (k12 and k21) and elimination rate 
constant (ke) were calculated using standard pharmacokinetic 
equations. Peripheral compartment morphine concentrations 
were calculated from mean data as described by Rowland 
and Tozer (Rowland and Tozer 1995).
Kidney function was evaluated by estimation of the 
creatinine clearance:
F equals 1.23 for men and 1.04 for women.
Statistical analysis
GraphPad Prism version 4.00 for Windows was used for all 
statistical analyses. Normally distributed data was tested for 
differences between the two treatment means with a t-test 
with two-tail p-value. A p-value of 0.05 was considered 
statistically signiﬁ  cant.
Results
All results are presented as mean values with standard 
deviation ( ± S.D.). All patients completed the study. Mean 
age, height and weight of the study subjects was 76.1 ± 4.5 
years, 167.4 ± 8.3 cm, and 77.8 ± 16.9 kg, respectively. 
Kidney function estimated by creatinine clearance was 
found to be normal except for two patients, where the kidney 
function was mildly reduced.
Pharmacokinetic analysis
The individual serum concentrations versus time profiles 
after IV administration of morphine, M3G and M6G, and 
oxycodone and noroxycodone are shown in Figure 1. 
Mean dose of morphine and oxycodone was 10744 ± 3017 
and 9393 ± 1015 nmol, respectively. Peak drug serum 
concentrations (Cmax) occurred at 15 min (end of infu-
sion) and were 150 ± 50 nmol/L and 98 ± 62 nmol/L for 
morphine and oxycodone, respectively. The metabolites 
M3G and M6G were measurable in the samples after 10 
and 20 min, respectively. Maximum concentration was 
reached at 75 min for both metabolites, for M3G 166 ± 46 
nmol/L and for M6G 30 ± 8 nmol/L. Oxymorphone was 
not quantifiable in any of the samples, but noroxycodone 
was measurable in 4 patients after 20 min. Maximum 
concentration was after 6 hours, 8 ± 4 nmol/L. In a single 
patient (no. 14) noroxycodone was not quantifiable in any 
of the samples.
A 2-compartment pharmacokinetic model best 
described the disposition of morphine and oxycodone. The 
best ﬁ  ts of morphine and oxycodone serum concentrations 
after applying the 2-compartment model are shown in 
Figure 2. The AUCs for morphine and oxycodone were 
159 ± 38 and 230 ± 196 nmol/L*hr, respectively. After 
approximately 4.3 hr the morphine serum concentrations 
were below the limit of quantiﬁ  cation. For oxycodone 
serum concentrations were still quantiﬁ  able at 11 hours. 
The results of the pharmacokinetic modeling are summa-
rized in Table 1. The estimated elimination half-lives for 
morphine and oxycodone were 2.7 ± 3.6 (range 0.8–11.6) 
and 3.1 ± 1.3 (range 1.1–4.8) hr, respectively. Volume of dis-
tribution at steady state (Vss) was estimated to be 243 ± 256 
(1)
CLcreatinine(ml/min)=
F*(140 age (years)* weight (kg))
p-cre
−
a atinine ( mol/L)Therapeutics and Clinical Risk Management 2007:3(5) 964
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and 277 ± 187 L, and clearance (CL) to be 1748 ± 623 
and 1206 ± 546 ml/min for morphine and oxycodone, 
respectively. The intercompartmental rate constants k12 
and k21 were for morphine 29.0 ± 36.9 and 1.9 ± 1.2 hr–1, 
and for oxycodone 11.44 ± 15.0 and 2.2 ± 0.9 hr–1. Maxi-
mum morphine peripheral compartment concentration 
was 20.8 nmol/L at 1.26 hr (tmax) and the elimination rate 
constant was 0.32 hr–1.
Figure 1 The individual serum concentrations versus time proﬁ  les of morphine, M3G and M6G after IV administration of morphine and of oxycodone and noroxycodone 
after IV administration of oxycodone. Please notice the different axes.Therapeutics and Clinical Risk Management 2007:3(5) 965
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Discussion
Drug disposition of both morphine and oxycodone followed a 
biexpontential decline with an initial rapid distribution phase 
followed by a slower elimination phase. The corresponding 
elimination half-life t½ was 2.7 ± 3.6 (range 0.8–11.6) and 
3.1 ± 1.3 (range 1.1–4.8) hr for morphine and oxycodone, 
respectively. For morphine, this is in agreement with what 
have been reported by others in healthy elderly volunteers 
(age 60–90 years) (Stanski et al 1978; Owen et al 1983; 
Baillie et al 1989; Sear et al 1989) and elderly patients (age 
61–83 years) (Stanski et al 1978; Owen et al 1983; Baillie 
et al 1989; Sear et al 1989). To the best of our knowledge, 
the pharmacokinetics of oxycodone has not earlier been 
investigated in an old population. The parameters found for 
oxycodone in this study are in agreement with those found 
in younger patients (t½: 2.3-5.9 hr, Vss: 140–279 L, and CL: 
49–1130 L) (Pöyhiä et al 1991, 2004; Leow, Smith, Watt, 
et al 1992; Leow, Smith, Williams, et al 1992; Leow et al 
1995; Kirvela et al 1996; Tallgren et al 1997).
The Vss of morphine has been found to considerably 
smaller in elderly patients than younger patients (Owen, 
Sitar, Berger, Brownell, Duke, and Mitenko 1983). How-
ever, the Vss found in this study is in range with what others 
have reported in both healthy volunteers (Stanski et al 1978; 
Patwardhan et al 1981; Owen et al 1983; Aitkenhead et al 
1984; Mazoit et al 1987; Baillie et al 1989; Hasselström and 
Säwe 1993; Westerling et al 1993, 1994, 1995; Stuart-Harris 
et al 2000) and patients (Stanski et al 1976, 1978; Murphy 
and Hug 1981; Säwe et al 1981; Moore et al 1984; Chauvin 
et al 1987; Säwe and Odar-Cederlöf 1987; Sear et al 1989, 
1989a, 1989b) regardless of age. Also clearance of morphine 
has been found to be signiﬁ  cantly reduced in elderly people 
(Owen et al 1983; Baillie et al 1989; Sear et al 1989) com-
pared to middle-aged as well as young people. In this study 
the CL of morphine was estimated to be 1748 ± 623 ml/min, 
which in agreement with the estimates found by others. For 
all studies, a great variability exists. However, there are some 
indications that the older the patients or study population are, 
the greater variability. In this study great inter-patient vari-
ability is seen in parent drugs as well as in the metabolites. 
Owen et al compared the disposition of morphine in elderly 
(age 60-69) with younger (age 23–28) healthy volunteers. 
The coefﬁ  cient of variance (% CV) was approximately 
twice as big in the elderly group compared to the younger 
group (Owen et al 1983). In this study the patients are older 
(age 70–84), and the % CV were even greater. Similar for 
oxycodone, great variability in the parameters exists. This 
great variability could be the explanation for the increased 
sensitivity observed in some elderly patients and complicates 
the treatment with morphine and oxycodone in this patient 
population.
Owen et al have also suggested that the increased anal-
gesic potency of morphine seen in elderly subjects might be 
related to increased peripheral compartment concentration 
in elderly subjects (Owen et al 1983). In the present study 
the patients were older (age 70–84), the %CV greater and 
the calculated peripheral compartment morphine concentra-
tions higher (dose difference taken into consideration). The 
analgesic effect of morphine may partly be related to altered 
disposition, however great variability exists and no easy 
correlation can be made. Animal and human studies indicate 
Figure 2 The best ﬁ  t of morphine (A) and oxycodone (B) serum concentrations 
after applying a 2-compartment pharmacokinetic model. Open circles are mean 
observed concentrations, while the solid lines are the mean predicted concentra-
tions using the best model. The dotted lines are 95% conﬁ  dence interval on the 
mean observed values.Therapeutics and Clinical Risk Management 2007:3(5) 966
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that also polymorphism may contribute to the variability of 
morphine efﬁ  cacy. However, the role of polymorphism for 
morphine is controversial. A recent report suggested that 
cancer patients homozygous for the 118G allele caused by 
the single nucleotide polymorphism at nucleotide position 
118 in the µ-opioid receptor gene, require higher doses of 
morphine to relieve pain (Klepstad et al 2004). Sawyer et al 
saw an effect on M3G and M6G-concentrations in patients with 
variations in the uridine diphosphate-glucuronosyltransferase 
(by UGT2B7*2), which indicates that inter-individual dif-
ferences in morphine glucuronidation may be the result of 
genetic variation (Saywer et al 2003). The pharmacokinetics 
and pharmacodynamics of M6G also seems to be related 
to A118G mutation of the human µ-opioid receptor gene 
resulting in reduced analgesic responses to M6G (Romberg 
et al 2004, 2005). Klepstad et al (2005) concludes in a 
short review that opioid efﬁ  cacy is partly related to inborn 
properties caused by genetic variability related to metabo-
lism, receptors and transporters, and that variation in other 
non-opioid biological systems may indirectly inﬂ  uence the 
pharmacology.
The role of polymorphism for oxycodone seems to be a 
bit clearer. The metabolic pathway for oxycodone is by the 
cytochrome P450 2D6 iso-enzyme. Approximately 10% of 
Caucasians are poor metabolizers, eg, they do not express this 
enzyme, and hence only form small amount of oxymorphone. 
As oxymorphone is not considered an important contributor 
to the analgesia seen after oxycodone administration, the 
component of polymorphism does not seem so important. 
However, as for morphine many factors inﬂ  uence the variation 
and the efﬁ  cacy of the drugs, and further studies investigating 
this is necessary.
As both the peripheral compartment concentrations and 
the variability increases with increasing age, treatment with 
morphine and probably oxycodone becomes more com-
plicated the older the patient is, and treatment should be 
conservative. Furthermore, it is important to acknowledge 
the risk of the potential life-threatening side effects, such as 
respiratory depression, with opioid during the acute phase 
of post-operative pain relief, which further supports a con-
servative treatment.
Conclusion
The increased and prolonged duration of pain relief after 
morphine administration, which has been seen in elderly 
patients, cannot, based on these ﬁ  ndings, be ascribed to 
changes in the pharmacokinetic parameters between elderly 
and younger patients. Similar for oxycodone, no changes in 
Table 1 Pharmacokinetic characteristics of morphine and oxycodone in elderly patients 
Patient no  Sex  Age  Weight  AUC  Alpha  Beta  t½ (hr)  V1 (L)  V2 (L)  Vss (L)  Cl
   (years)  (kg)  (nmol/L*hr)  (hr-1)  (hr-1)         (ml/min)
Morphine
1  F 73  49  105.60  5.71 0.51 1.35  90.21  135.71  225.92  2375.62
2  F  81  57  185.00  38.72 0.60  1.15  10.09  84.04 94.13  1120.08
4  F  84  73  199.20  120.08 0.44  1.59  3.79  129.23 133.02  1133.17
6  M  71  96  149.10  114.33 0.65  1.06  4.02  158.64 162.66  2730.84
8  M  78  84  98.18  6.52 0.06 11.58 33.08  826.71  859.79  1358.95
9  F  70  64  182.90  22.61 0.88  0.79  12.09  56.52 68.61  1352.59
 M  77  96  183.20  10.04  0.40  1.72  25.20  134.34  159.54  1646.48
13
16 M  76  118  166.00  9.66  0.34  2.06  32.20  209.46  241.66  2268.63
Mean   76.25  79.63  158.65  40.96  0.49  2.66  26.34  216.83  243.17  1748.30
SD   4.83 23.19  38.07  48.33  0.24  3.63 28.37  250.65  256.02  623.50
Oxcodone
3 F  73  72  205.10  11.24  0.22  3.13  41.97  171.25  213.22  865.07
5 M  74  86  299.00  9.29  0.23  3.01  25.23  126.86  152.08  689.07
7 M  80  74  683.40  7.39  0.14  4.82  26.46  92.76  119.22  309.28
10  F 74  79  172.00  6.46 0.41 1.67  81.54  103.23  184.77  1414.30
11  F 82  74  63.86  5.82 0.18 3.89  221.72  194.21  415.93  1271.62
12 F  72  59  137.40  61.67  0.65  1.07  9.90  126.40  136.30  1749.93
14 M  71  83  119.60  8.99  0.16  4.28  152.44  511.92  664.36  1919.40
15 M  81  80  157.40  13.81  0.23  3.06  40.88  285.90  326.78  1425.57
Mean   75.88  75.88  229.72  15.59  0.28  3.12  75.02  201.57  276.58  1205.53
SD   4.39 8.34 195.65  18.80  0.17  1.26 74.54  139.97  186.97  546.19 Therapeutics and Clinical Risk Management 2007:3(5) 967
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the pharmacokinetic could be found when comparing the 
parameters found in elderly patients with those from younger 
healthy volunteers. A great variability within the individual 
pharmacokinetic parameters was seen for both drugs.
As age-related drug effect could not solely be translated to 
alterations in pharmacokinetics, in order to fully understand 
the pharmacological basis for these changes in the elderly 
people, pharmacodynamic parameters must also be considered 
when conducting such studies. Therefore, we recommend that 
treatment with morphine and oxycodone in elderly patients is 
initiated very conservatively and is titrated slowly to effect.
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